Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01844232 · ClinicalTrials.gov registry record · Phase 3
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
A Phase 3 study, sponsored by RVL Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT01844232 is a Phase 3 study that has completed, run by RVL Pharmaceuticals. The registered enrollment target is 150 participants.
The verdict
NCT01844232, a Phase 3 study, has completed, sponsored by RVL Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS) subjects with spasticity. All subjects in this study will receive arbaclofen in the extended release tablet formulation.
Interventions
- DRUG arbaclofen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2013-04 |
| Est. Completion | 2015-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01844232
The ClinicalTrials.gov registry entry for NCT01844232 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is RVL Pharmaceuticals, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which arbaclofen is the first listed.
NCT01844232 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01844232 about?
NCT01844232 is a clinical study titled "One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity". Clinical protocol OS440-3003 is a multicenter, open-label, non-randomized, uncontrolled, dose escalation study to evaluate the safety and tolerability of Arbaclofen Extended Release Tablets over 1 year in Multiple Sclerosis (MS) subjects with spasticity. All subjects in this study will receive arbac...
What is the current status of trial NCT01844232?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2013-04. Estimated completion is 2015-01.
What interventions are being tested in trial NCT01844232?
The interventions under investigation include: arbaclofen (DRUG).
Who is sponsoring clinical trial NCT01844232?
This trial is sponsored by RVL Pharmaceuticals, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.